Evidence map›Paper›PMID 38983711›Full record

ReviewOpen forum infectious diseases2024

Long-acting HIV Treatments: Study Design, Logistics, and Access.

Nicholas A Murdock, Nayri E Alajaji, Robin Schaefer, Cheriko A Boone, Rafael E Campo, Gregory J Dore, Monica Gandhi, J Rafael Gorospe, Roy M Gulick, Sally L Hodder and 6 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Nicholas A MurdockForum for Collaborative Research, University of California, Berkeley, Washington, DC, USA.
Nayri E AlajajiForum for Collaborative Research, University of California, Berkeley, Washington, DC, USA.
Robin SchaeferForum for Collaborative Research, University of California, Berkeley, Washington, DC, USA.ORCID https://orcid.org/0000-0003-4733-4692
Cheriko A BooneTAG Treatment Action Group Inc., New York, New York, USA.
Rafael E CampoMerck & Co., Inc., Upper Gwynedd, Pennsylvania, USA.
Gregory J DoreThe Kirby Institute, University of New South Wales, Sydney, NSW, Australia.
Monica GandhiDepartment of Medicine, University of California at San Francisco (UCSF), San Francisco, California, USA.ORCID https://orcid.org/0000-0002-7025-1994
J Rafael GorospeOffice of AIDS Research, National Institutes of Health, Bethesda, Maryland, USA.
Roy M GulickDepartment of Medicine, Weill Cornell Medicine, New York, New York, USA.
Sally L HodderWest Virginia Clinical and Translational Science Institute, West Virginia University School of Medicine, Morgantown, West Virginia, USA.
Jonathan LiuUniversity of Southern California, Los Angeles, California, USA.
Martin S RheeGilead Sciences, Foster City, California, USA.
James F RooneyGilead Sciences, Foster City, California, USA.
Vani VannappagariViiV Healthcare, Durham, North Carolina, USA.
Timothy WilkinDepartment of Medicine, Weill Cornell Medicine, New York, New York, USA.
Veronica MillerForum for Collaborative Research, University of California, Berkeley, Washington, DC, USA.

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
“Hair Lengthening”: Using Hair Levels to Interpret Long-Acting PrEP Studies.R37AI098472 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Monica Gandhi · 2023 to 2026
$3.2M
Unraveling the intersection of substance use, inflammation, and HIV via hair levelsR01DA059291 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Monica Gandhi, Pamina Mae Gorbach · 2023 to 2026
$3.0M
NIAID NIH HHS R37 AI098472NIDA NIH HHS R01 DA059291
6 · The paper itself

Abstract

New long-acting HIV treatment products have the potential to change the HIV epidemic in the United States and globally. Phase 3 clinical trials of HIV treatments tend to underrepresent populations bearing a disproportionate burden of the HIV epidemic-including women, racial minorities, trans and gender-diverse people, older adults, the unhoused, people who inject drugs, those in rural areas, individuals with mental illness, and other marginalized groups. These populations commonly face significant challenges in adhering to daily HIV treatment regimens. Conducting clinical trials of long-acting treatment targeting specific unmet medical needs of these populations can improve understanding of optimal care approaches, broaden the indication for use of long-acting products, and inform treatment guidelines, all of which can influence reimbursement and access policies. Innovative trial designs and programmatic implementation can improve inclusivity for long-acting therapy. This article summarizes discussions of a multistakeholder workshop on study designs for long-acting HIV treatments.

Indexed as

HIV-1inclusivitylong-acting HIV treatmentmarginalized populationstrial design

Identifiers

PMID38983711
PMCPMC11232696

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.